Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: An antenna structure able to function in a 5G environment is disposed on a supporting member within an electronic device. The antenna structure includes a large number of antenna arrays, the antenna arrays include antenna units arranged in a line, and current is fed to each of the antenna units. A wireless communication device with enhanced transmission rates is also provided.

Abstract: An audio playback device receives an instruction from a user to select a target voice model from a plurality of voice models and assigns the target voice model to a target character in a text. The audio playback device also transforms the text into a speech, and during the process of transforming the text into the speech, transforms sentences of the target character in the text into the speech of the target character according to the target voice model.

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

Abstract: Provided are a signal transforming method and a signal transforming device. For example, the signal transforming method includes determining a minimum-value matrix and a maximum-value matrix with respect to elements of a matrix used in frequency transformation, wherein the minimum-value matrix is configured of elements of minimum value and the maximum-value matrix is configured of elements of maximum value; determining a maximum threshold value of a result value of a function indicating at least one selected from transform distortion, normalization, and orthogonality of the matrix; determining a transform matrix configured of elements that are greater than the elements of the minimum-value matrix and less than the elements of the maximum-value matrix at respective positions of the matrix, and in which the result value of the function is less than the maximum threshold value; and transforming an input signal by using the determined transform matrix.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

Abstract: According to a method for pushing a notification provided in some embodiments of the present disclosure, a to-be-notified event is obtained; a first notification condition and a second notification condition are determined; a first notification page is displayed on the display when the first notification condition is met, to display, to a user, first association information when the first notification condition is met, for example, event status information, to-be-executed behavior information, and operation association information; and a second notification page is displayed on the display when the second notification condition is met after the first notification page is displayed, to display, to the user, second association information when the second notification condition is met. A plurality of notification pages are pushed for a to-be-notified event, and each notification page is pushed when a notification condition is met as the event develops.

Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: A voice interactive device includes a semantic analyzing module, a tone analyzing module, a speaker classification determining module and a dialogue sentence database. The semantic analyzing module is configured to analyze a semantic meaning of speaking sentence from a speaker. The tone analyzing module is configured to analyze a tone of the speaking sentence. The speaker classification determining module is configured to determine that the speaker belongs to one of a plurality of speaker classification types according to the semantic meaning and the tone. The dialogue sentence database stores a plurality of relationships between speaker classifications and response sentences. The dialogue sentence generating module is configured to generate a response sentence corresponding to the speaker according to the relationships between speaker classifications and response sentences. The voice generator is configured to output a response voice of the response sentence.

Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: Provided are a signal transforming method and a signal transforming device. For example, the signal transforming method includes determining a minimum-value matrix and a maximum-value matrix with respect to elements of a matrix used in frequency transformation, wherein the minimum-value matrix is configured of elements of minimum value and the maximum-value matrix is configured of elements of maximum value; determining a maximum threshold value of a result value of a function indicating at least one selected from transform distortion, normalization, and orthogonality of the matrix; determining a transform matrix configured of elements that are greater than the elements of the minimum-value matrix and less than the elements of the maximum-value matrix at respective positions of the matrix, and in which the result value of the function is less than the maximum threshold value; and transforming an input signal by using the determined transform matrix.

Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.